Form 8-K - Current report:
SEC Accession No. 0001628280-23-017419
Filing Date
2023-05-11
Accepted
2023-05-11 08:05:58
Documents
13
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20230511.htm   iXBRL 8-K 36317
2 EX-99.1 a05-11x2023xpressrelease.htm EX-99.1 58541
  Complete submission text file 0001628280-23-017419.txt   246932

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20230511.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20230511_lab.xml EX-101.LAB 24832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20230511_pre.xml EX-101.PRE 13053
7 EXTRACTED XBRL INSTANCE DOCUMENT prme-20230511_htm.xml XML 12923
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 23908942
SIC: 2836 Biological Products, (No Diagnostic Substances)